Astria Therapeutics, Inc. (ATXS)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 10:37AM EDT. Market open.
| Previous close | 9.57 |
| Open | 9.61 |
| Bid | 9.98 x 300 |
| Ask | 10.15 x 200 |
| Day's range | 9.61 - 10.25 |
| 52-week range | 4.26 - 16.90 |
| Volume | |
| Avg. volume | 1,028,418 |
| Market cap | 552.426M |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS)
Astria Therapeutics Inc (NASDAQ:ATXS), a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat debilitating diseases, has reported an insider sale according to a recent SEC filing.
- Simply Wall St.
Astria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 53% of the company
Key Insights Significantly high institutional ownership implies Astria Therapeutics' stock price is sensitive to their...
- GuruFocus.com
Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc
Christopher Morabito, Chief Medical Officer of Astria Therapeutics Inc (NASDAQ:ATXS), has sold 10,000 shares of the company on January 29, 2024, according to a recent SEC Filing.
© 2024 Yahoo. All rights reserved.